RBC Capital maintains Exelixis at Sector Perform, raises price target to $58 from $51
RBC Capital kept Exelixis at Sector Perform, raising its price target to $58 from $51. This implies a 12.4% downside from the Oct 29 close of $66.20. Recent analyst targets range from $51 to $65.
How this was made
The 30-second read
Why it matters
The downgrade in price target may temper recent gains, but the Sector Perform rating keeps the stock neutral.
Market read
Analyst price target change is a modest catalyst for Exelixis, offering limited trading impetus.
What to watch
Potential pipeline milestones or partnership news not covered in this brief could offset the target cut.
Background
RBC Capital maintains a Sector Perform rating for Exelixis while adjusting its price target.
Ticker impact
RBC Capital raised its price target for Exelixis to $58 from $51, a new analyst recommendation.
potential modest pressure as the market prices in the lower target versus current price
The new target is still below the recent close, so investors may view the stock as overvalued and may sell or hold off buying.
Market effects
Slightly bearish for biotech sector as analyst targets tighten.
Minimal impact on broader US market.
Limited to investors tracking Exelixis and biotech peers.
Counterpoint
Despite the lower target, the stock may rally if upcoming trial data exceeds expectations.
Key entities
- AnalystRBC Capital
Equity research firm providing the rating and price target.
- CompanyExelixis
Biotech firm subject of the analyst update.
